Lixte Biotechnology Holdings Stock Beneish M Score

LIXT Stock  USD 3.22  0.13  3.88%   
This module uses fundamental data of Lixte Biotechnology to approximate the value of its Beneish M Score. Lixte Biotechnology M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Check out Lixte Biotechnology Piotroski F Score and Lixte Biotechnology Altman Z Score analysis.
  
Cash Flow To Debt Ratio is likely to gain to 14.36 in 2024, despite the fact that Net Debt is likely to grow to (4 M). At this time, Lixte Biotechnology's Tangible Book Value Per Share is comparatively stable compared to the past year. Graham Number is likely to gain to 12.08 in 2024, whereas Operating Cash Flow Per Share is likely to drop (2.35) in 2024.
At this time, it appears that Lixte Biotechnology is an unlikely manipulator. The earnings manipulation may begin if Lixte Biotechnology's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Lixte Biotechnology executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Lixte Biotechnology's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-7.1
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables

N/A

Focus
Asset Quality

N/A

Focus
Expense Coverage

N/A

Focus
Gross Margin Strengs

N/A

Focus
Accruals Factor

N/A

Focus
Depreciation Resistance

N/A

Focus
Net Sales Growth

N/A

Focus
Financial Leverage Condition

1.87

Focus

Lixte Biotechnology Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Lixte Biotechnology's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Net Receivables12.3 K12.9 K
Notably Down
Slightly volatile
Total Assets2.2 M4.3 M
Way Down
Slightly volatile
Total Current Assets2.2 M4.2 M
Way Down
Slightly volatile
Depreciation And Amortization4.8 K5.1 K
Notably Down
Slightly volatile
Selling General AdministrativeK4.2 K
Notably Down
Slightly volatile
Total Current Liabilities290.7 K313.9 K
Significantly Down
Slightly volatile

Lixte Biotechnology Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Lixte Biotechnology's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Lixte Biotechnology in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Lixte Biotechnology's degree of accounting gimmicks and manipulations.

About Lixte Biotechnology Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation And Amortization

4,835.73

At this time, Lixte Biotechnology's Depreciation And Amortization is comparatively stable compared to the past year.

Lixte Biotechnology Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Lixte Biotechnology. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201920202021202220232024 (projected)
Total Assets2.7M5.2M5.1M5.6M4.3M2.2M
Total Current Assets2.7M5.2M5.1M5.6M4.2M2.2M
Depreciation And Amortization2.5K5.2K626.011.2K5.1K4.8K
Selling General Administrative1.7M2.0M5.0M5.0M4.2K4.0K
Total Current Liabilities237.9K216.5K302.9K394.8K313.9K290.7K
Net Debt(2.6M)(5.1M)(4.8M)(5.4M)(4.2M)(4.0M)
Short Term Debt(210.9K)(237.9K)(302.9K)(394.8K)(313.9K)(298.2K)
Operating Income(2.5M)(3.3M)(6.7M)(6.3M)(5.1M)(4.8M)
Total Cash From Operating Activities(1.7M)(2.1M)(4.1M)(4.6M)(4.3M)(4.1M)

About Lixte Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lixte Biotechnology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lixte Biotechnology's short interest history, or implied volatility extrapolated from Lixte Biotechnology options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lixte Biotechnology is a strong investment it is important to analyze Lixte Biotechnology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lixte Biotechnology's future performance. For an informed investment choice regarding Lixte Stock, refer to the following important reports:
Check out Lixte Biotechnology Piotroski F Score and Lixte Biotechnology Altman Z Score analysis.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Is Lixte Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.66)
Return On Assets
(0.64)
Return On Equity
(1.11)
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.